BUSINESS SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2011

Segment Reporting [Abstract]

Business Segment Information [Text Block]

Note 3. BUSINESS SEGMENT INFORMATION

The Company operates in a singleBioPharmaceuticals segment which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and a global supply chain organization are utilized and responsible for the development and delivery of products to the market. Products are distributed and sold through regional organizations that serve the United States; Europe; Latin America, Middle East, and Africa; Japan, Asia Pacific and Canada; and Emerging Markets defined as Brazil, Russia, India, China and Turkey. The business is also supported by global corporate staff functions. The segment information presented below is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Net sales of key products were as follows:

		Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions		2011		2010		2011		2010
PLAVIX*		$	1,865	$	1,627	$	3,627	$	3,293
AVAPRO*/AVALIDE*			251		307		541		621
ABILIFY*			706		633		1,330		1,250
REYATAZ			396		357		762		730
SUSTIVA Franchise			371		331		714		666
BARACLUDE			292		223		567		439
ERBITUX*			173		172		338		338
SPRYCEL			193		132		365		263
YERVOY			95		-		95		-
ORENCIA			228		178		427		347
NULOJIX			2		-		2		-
ONGLYZA/KOMBIGLYZE			112		28		193		38
Mature Products and All Other			750		780		1,484		1,590
	Net Sales	$	5,434	$	4,768	$	10,445	$	9,575

Segment income excludes the impact of significant items not indicative of current operating performance or ongoing results, and earnings attributed to Sanofi and other noncontrolling interest. The reconciliation to earnings before income taxes was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2011		2010		2011		2010
BioPharmaceuticals segment income	$	1,299	$	1,180	$	2,587	$	2,413
Reconciling items:
Restructuring and other charges		(68)		(77)		(139)		(332)
Litigation recovery		-		-		102		-
Upfront, milestone and other licensing payments		(50)		(17)		(138)		(72)
In-process research and development impairment		-		-		(15)		-
Product liability charges		-		-		(26)		-
Noncontrolling interest		609		506		1,186		1,035
Earnings before income taxes	$	1,790	$	1,592	$	3,557	$	3,044